Costs and consequences of direct-to-consumer advertising for clopidogrel in Medicaid


Related Publications

Suter E, Misfeldt R, Mallinson S, Wilhelm A, Boakye O, Marchildon G, et al. Comparative Review of the Policy Landscape of Team-based Primary Health Care Service Delivery in Western Canada. Alberta Health Services; 2014.
Laberge M, Pang J, Walker K, Wong ST, Hogg W, Wodchis WP. QUALICOPC (Quality and Costs of Primary Care) Canada: A focus on the aspects of primary care most highly rated by current patients of primary care practices. Ottawa, ON: Canadian Foundation for Healthcare Improvement; 2014.
McGregor MJ, Abu-Laban RB, Ronald L, McGrail KM, Andrusiek D, Baumbusch J, et al. Nursing Home Characteristics Associated with Resident Transfers to Emergency Department. Canadian Journal on Aging. 2012;33(1):38-48.
Koehoorn M, McLeod CB, Fan JK, McGrail KM, Barer ML, Cote P, et al. Do private clinics or expedited fees improve wait- or return-to-work times for injured workers following knee surgery? Healthcare Policy. 2011;5(3):17-26.
Sutherland JM, Barer ML, Evans RG, Crump RT. Will paying the piper change the tune? Healthcare Policy. 2011;6(4):16-24.

Publication Topics

Costs and consequences of direct-to-consumer advertising for clopidogrel in Medicaid

Publication TypeJournal Article
Year of Publication2009
AuthorsLaw M, Soumerai SB, Adams AS, Majumdar SR
JournalArchives of Internal MedicineArch.Intern.Med.
Pages1969 - 1974
Date Published2009
KeywordsAdvertising as Topic/economics/trends, Consumer Satisfaction/economics, Drug Costs, Health Expenditures, Humans, Information Dissemination, Mass Media, Medicaid/economics, Patient Participation/economics, Pharmacies/economics, Physician's Practice Patterns/economics, Platelet Aggregation Inhibitors/administration & dosage/economics, Ticlopidine/administration & dosage/analogs & derivatives/economics, United States
AbstractBACKGROUND: Direct-to-consumer advertising (DTCA) is assumed to be a major driver of rising pharmaceutical costs. Yet, research on how it affects costs is limited. Therefore, we studied clopidogrel, a commonly used and heavily marketed antiplatelet agent, which was first sold in 1998 and first direct-to-consumer advertised in 2001. METHODS: We examined pharmacy data from 27 Medicaid programs from 1999 through 2005. We used interrupted time series analysis to analyze changes in the number of units dispensed, cost per unit dispensed, and total pharmacy expenditures after DTCA initiation. RESULTS: In 1999 and 2000, there was no DTCA for clopidogrel; from 2001 through 2005, DTCA spending exceeded $350 million. Direct-to-consumer advertising did not change the preexisting trend in the number of clopidogrel units dispensed per 1000 enrollees (P = .10). However, there was a sudden and sustained increase in cost per unit of $0.40 after DTCA initiation (95% confidence interval, $0.31-$0.49; P < .001), leading to an additional $40.58 of pharmacy costs per 1000 enrollees per quarter thereafter (95% confidence interval, $22.61-$58.56; P < .001). Overall, this change resulted in an additional $207 million in total pharmacy expenditures. CONCLUSIONS: Direct-to-consumer advertising was not associated with an increase in clopidogrel use over and above preexisting trends. However, Medicaid pharmacy expenditures increased substantially after the initiation of DTCA because of a concomitant increase in the cost per unit. If drug price increases after DTCA initiation are common, there are important implications for payers and for policy makers in the United States and elsewhere.
Citation Key384